In This Article:
MediWound and Vericel Corporation’s thermal burn treatment, NexoBrid (anacaulase-bcdb) has been approved by the US Food and Drug Administration (FDA) for eschar removal in paediatric patients with deep partial-thickness and/or full-thickness thermal burns.
The current approval builds on MediWound’s previous approval for the same indication in the adult population in January. It generated $19m in sales last year, as per MediWound’s financials. GlobalData expects NexoBrid sales to maintain the upward trajectory and generate over $98m in sales by 2030.
NexoBrid is a gel consisting of a sterile mixture of proteolytic enzymes, which selectively eliminate burn eschar within four hours without causing harm to surrounding viable tissue. It was developed by MediWound, with Vericel acquiring commercialisation rights to NexoBrid in North America in 2019.
The FDA approval for NexoBrid was based on the positive Phase III Children Innovative Debridement Study (CIDS) (NCT02278718). The trial enrolled 145 children under 17 years of age and compared NexoBrid with the current standard of care for burns. The gel removed unhealthy tissue in the burn area, allowing surgeons to properly gauge thickness and evaluate if surgical intervention is needed.
Another proteolytic enzyme gel in MediWound’s pipeline is EscharEx. The company recently published positive data from a Phase II ChronicEx trial (NCT03588130) showing its efficacy in treating venous leg ulcers. MediWound plans to start a Phase III trial evaluating EscharEx as a treatment for venous leg ulcers in the second half of this year. The company also plans to investigate EscharEx in another chronic wound condition, namely diabetic foot ulcers in the second half of 2025.
The wound care management market is expected to total $38.8bn by 2030, with a CAGR of 3.4%. Multiple companies have made advances in managing burns. Spectral AI is developing a diagnostics platform DeepView that can help predict wound healing outcomes and support clinical decision-making.
Kerecis has developed fish skin-derived tissue-transplant products for treating burns. Its Omega3 GraftGuide product is approved by the FDA for the management of chronic wounds, including diabetic, vascular, and other hard-to-heal wounds.
"MediWound and Vericel win FDA paediatric label expansion for NexoBrid" was originally created and published by Medical Device Network, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.